FrancophonIA/ELRC3.0 huggingface dataset:
English: ● Zirabev can increase the risk of developing a weak heart.
Croatian: Zirabev može povećati rizik od slabljenja srca.
English: An increased incidence of post-operative bleeding or wound healing complication occurring within 60 days of major surgery was observed if the patient was being treated with bevacizumab at the time of surgery.
Croatian: Opažena je povećana incidencija postoperativnog krvarenja ili komplikacija pri zacjeljivanju rana unutar 60 dana od većeg kirurškog zahvata ako je bolesnik primao bevacizumab u vrijeme kirurškog zahvata.
English: Post-marketing adverse reactions are included in both Tables 1 and 2, where applicable.
Croatian: Nuspojave prijavljene nakon stavljanja lijeka u promet uključene su u tablice 1 i 2 (kako je odgovarajuće).
English: In addition, hypertension (including hypertensive crisis), elevated creatinine, and neurological symptoms were observed in some of these patients.
Croatian: Osim toga, u nekih su od ovih bolesnika opaženi hipertenzija (uključujući hipertenzivnu krizu), povišena razina kreatinina i neurološki simptomi.
English: The pharmacokinetics of bevacizumab was well characterized by the paediatric population PK model for 70 patients in Study BO20924 ((1.4 to 17.6 years; 11.6 to 77.5 kg) and 59 patients in Study BO25041 (1 to 17 years; 11.2 to 82.3 kg).
Croatian: Farmakokinetika bevacizumaba dobro je okarakterizirana pedijatrijskim populacijskim farmakokinetičkim modelom za 70 bolesnika u ispitivanju BO20924 (od 1,4 do 17,6 godina; od 11,6 do 77,5 kg) te 59 bolesnika u ispitivanju BO25041 (od 1 do 17 godina; od 11,2 do 82,3 kg).
English: These include a decreased number of white cells in the blood, in particular neutrophils (one type of white blood cell which helps protect against infections) in the blood; presence of protein in the urine; decreased blood potassium, sodium or phosphorous (a mineral); increased blood sugar; increased blood alkaline phosphatase (an enzyme); increased serum creatinine (a protein measured by a blood test to see how well your kidneys are working); decreased haemoglobin (found in red blood cells, which carry oxygen), which may be severe.
Croatian: One uključuju: smanjen broj bijelih krvnih stanica, osobito neutrofila (vrsta bijelih krvnih stanica koja pomaže u zaštiti od infekcija) u krvi; prisutnost proteina u mokraći; smanjenu razinu kalija, natrija ili fosfora (mineral) u krvi; povišenu razinu šećera u krvi; povišenu razinu alkalne fosfataze (enzim) u krvi; povišenu serumsku razinu kreatinina (protein čija se razina određuje krvnom pretragom kako bi se utvrdilo kako Vam rade bubrezi); smanjenu razinu hemoglobina (nalazi se u crvenim krvnim stanicama koje prenose kisik), koja može biti ozbiljna.
English: IgGs are known to cross the placenta, and bevacizumab is anticipated to inhibit angiogenesis in the foetus, and thus is suspected to cause serious birth defects when administered during pregnancy.
Croatian: Poznato je da molekule IgG-a mogu proći kroz posteljicu, a pretpostavlja se da bevacizumab može spriječiti angiogenezu u fetusa te se stoga sumnja da bi mogao izazvati teške urođene anomalije ako se primjenjuje tijekom trudnoće.
English: Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells.
Croatian: Bevacizumab se veže na krvožilni endotelni faktor rasta (engl. vascular endothelial growth factor, VEGF), ključni medijator vaskulogeneze i angiogeneze, i time inhibira vezivanje VEGF-a za receptore Flt-1 (VEGFR-1) i KDR (VEGFR-2) na površini endotelnih stanica.
English: Close observation of the patient during and following the administration of bevacizumab is recommended as expected for any infusion of a therapeutic humanised monoclonal antibody.
Croatian: Preporučuje se pomno nadzirati bolesnika tijekom i nakon primjene bevacizumaba, kao što je i uobičajeno kod svake infuzijske primjene terapijskog humaniziranog monoklonskog protutijela.
English: ● if you are allergic (hypersensitive) to Chinese hamster ovary (CHO) cell products or to other recombinant human or humanised antibodies.
Croatian: ● ste alergični (preosjetljivi) na proizvode stanica jajnika kineskog hrčka ili druga rekombinantna ljudska ili humanizirana protutijela
English: GI-vaginal fistulae in study GOG-0240
Croatian: Gastrointestinalno-vaginalne fistule u ispitivanju GOG-0240
English: Use of irinotecan- or oxaliplatin-containing regimen was switched depending on first-line usage of either oxaliplatin or irinotecan.
Croatian: Primjena režima koji sadrže irinotekan ili oksaliplatin promijenjena je ovisno o tome je li u prvoj liniji primijenjen oksaliplatin ili irinotekan.
English: • AVF2192g: In combination with bolus 5-FU/FA for a total of 6 weeks of each 8 week-cycle (Roswell Park regimen) in patients who were not optimal candidates for first-line irinotecan treatment.
Croatian: ● AVF2192g: u kombinaciji s bolusom 5-FU/FA kroz ukupno 6 tjedana tijekom svakog osmotjednog ciklusa (Roswell-Parkov režim) u bolesnika koji nisu bili optimalni kandidati za primjenu irinotekana u prvoj liniji liječenja
English: The safety and efficacy of the recommended dose (5 mg/kg of body weight every two weeks) in metastatic carcinoma of the colon or rectum were studied in three randomised, active-controlled clinical trials in combination with fluoropyrimidine-based first-line chemotherapy.
Croatian: Sigurnost i djelotvornost preporučene doze (5 mg/kg tjelesne težine svaka dva tjedna) u liječenju metastatskog karcinoma kolona ili rektuma ispitane su u tri randomizirana, aktivno kontrolirana klinička ispitivanja u kombinaciji s kemoterapijom prve linije baziranom na fluoropirimidinu.
English: These therapies in combination with Zirabev may increase the risk of severe side effects.
Croatian: Ove terapije u kombinaciji s lijekom Zirabev mogu povećati rizik od teških nuspojava.
English: Enrolment in Arm 3 was discontinued, as pre-specified, once safety of bevacizumab with the IFL regimen was established and considered acceptable.
Croatian: Prema planu ispitivanja uključivanje u treću skupinu prekinuto je čim je utvrđena i prihvatljivom ocijenjena sigurnost primjene bevacizumaba u kombinaciji s režimom IFL.
English: The 649 randomised patients (641 treated) had Karnofsky Performance Status (KPS) of ≥ 70%, no CNS metastases and adequate organ function.
Croatian: Randomizirano je 649 bolesnika (od kojih je 641 liječen) funkcionalnog statusa prema Karnofskom ≥ 70 %, bez metastaza u središnjem živčanom sustavu i sa zadovoljavajućom funkcijom organa.
English: Analyses of the clinical safety data suggest that the occurrence of hypertension and proteinuria with bevacizumab therapy are likely to be dose-dependent.
Croatian: Analize kliničkih podataka o sigurnosti primjene upućuju na to da pojava hipertenzije i proteinurije tijekom terapije bevacizumabom vjerojatno ovisi o dozi.
English: Day 1, prior to XELOX, q 3 weeks
Croatian: 1. dana, prije primjene režima XELOX, svaka 3 tjedna
English: However, patients who developed venous thrombosis while receiving therapy did not appear to have an increased rate of Grade 3 or above bleeding when treated with a full dose of warfarin and bevacizumab concomitantly (NCI-CTCAE v.3).
Croatian: Međutim, bolesnici u kojih se tijekom liječenja razvila venska tromboza nisu imali povećanu stopu krvarenja stupnja 3 ili višeg stupnja pri istodobnom liječenju punom dozom varfarina i bevacizumaba (NCI-CTCAE v.3).
English: Tumour-associated haemorrhage was also seen rarely in other tumour types and locations, including cases of central nervous system (CNS) bleeding in patients with CNS metastases (see section 4.4).
Croatian: Krvarenja povezana s tumorom rijetko su primijećena i kod drugih vrsta tumora te drugih lokacija, uključujući slučajeve krvarenja u središnjem živčanom sustavu u bolesnika s metastazama u središnjem živčanom sustavu (vidjeti dio 4.4).
English: The overall safety profile of bevacizumab is based on data from over 5,700 patients with various malignancies, predominantly treated with bevacizumab in combination with chemotherapy in clinical trials.
Croatian: Ukupan sigurnosni profil bevacizumaba temelji se na podacima prikupljenima u više od 5700 bolesnika s raznim malignim bolestima, koji su u kliničkim ispitivanjima uglavnom bili liječeni bevacizumabom u kombinaciji s kemoterapijom.
English: Once the vial has been opened, the dilution must be performed immediately.
Croatian: Kada se bočica otvori, sadržaj se odmah mora razrijediti.
English: In cases of internal fistula not arising in the gastrointestinal tract, discontinuation of Zirabev should be considered.
Croatian: U slučajevima nastanka unutarnje fistule izvan gastrointestinalnog trakta, potrebno je razmotriti prekid primjene lijeka Zirabev.
English: The efficacy data from trials AVF0780g and AVF2192g investigating bevacizumab in combination with 5-FU/FA-chemotherapy are summarised in Table 5.
Croatian: Podaci o djelotvornosti iz ispitivanja AVF0780g i AVF2192g, u kojima je ispitivana primjena bevacizumaba u kombinaciji s režimom kemoterapijom 5-FU/FA, sažeti su u tablici 5.
English: In Study BO20924, bevacizumab exposure was generally lower compared to a typical adult patient at the same dose.
Croatian: U ispitivanju BO20924, izloženost bevacizumabu načelno je bila niža nego u tipičnog odraslog bolesnika pri istoj dozi.
English: Systemic adverse reactions including non-ocular haemorrhages and arterial thromboembolic reactions have been reported following intravitreal injection of VEGF inhibitors.
Croatian: Prijavljene su sistemske nuspojave, uključujući neokularna krvarenja i arterijske tromboembolijske reakcije nakon intravitrealne injekcije inhibitora VEGF-a.
English: When used for patients with breast cancer, it will be administered with a chemotherapy medicinal product called paclitaxel.
Croatian: Kada se koristi za bolesnice s rakom dojke, primjenjuje se uz kemoterapijski lijek koji se zove paklitaksel.
English: Zirabev will be administered in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy.
Croatian: Zirabev će se davati u kombinaciji s paklitakselom i cisplatinom ili, alternativno, paklitakselom i topotekanom u bolesnica koje ne mogu primiti terapiju platinom.
English: The findings ranged from asymptomatic declines in left ventricular ejection fraction to symptomatic CHF, requiring treatment or hospitalisation.
Croatian: Nalazi su se kretali od asimptomatskih smanjenja istisne frakcije lijeve klijetke do simptomatskog kongestivnog zatajenja srca koje je zahtijevalo liječenje ili hospitalizaciju.
English: This is consistent with results in patients in other studies of metastatic breast cancer who did not receive concurrent anthracycline treatment (NCI-CTCAE v.3) (see section 4.8).
Croatian: To se podudara s nalazima bolesnika iz drugih ispitivanja metastatskog raka dojke koji nisu istodobno liječeni antraciklinima (NCI-CTCAE v.3) (vidjeti dio 4.8).
English: Do not stop treatment with Zirabev unless you have discussed this with your doctor.
Croatian: Nemojte prekinuti liječenje lijekom Zirabev bez prethodnog savjetovanja s liječnikom.
English: Patients and percentage of patients with best overall response of confirmed CR or PR; percentage calculated on patients with measurable disease at baseline 95% CI for one sample binomial using Pearson-Clopper method Approximate 95% CI for difference of two rates using Hauck-Anderson method log-rank test (stratified) Primary analysis was performed with a data cut-off date of 12 December 2012 and is considered the final analysis
Croatian: Kaplan-Meierove procjene Bolesnice i postotak bolesnica s najboljim ukupnim odgovorom koji uključuje potvrđeni potpun ili djelomičan odgovor; postotak izračunat na temelju bolesnica s mjerljivom bolešću na početku ispitivanja 95 % CI za binomski test na jednom uzorku primjenom Pearson-Clopperove metode Približno 95% CI za razliku između dviju stopa primjenom Hauck-Andersonove metode log-rank test (stratificirani) Primarna analiza provedena je na temelju podataka prikupljenih do 12. prosinca 2012. i smatra se završnom analizom Analiza nakon praćenja provedena je na temelju podataka prikupljenih do 7. ožujka 2014. p-vrijednost navedena je samo u ilustrativne svrhe
English: Patients with non-small cell lung cancer treated with bevacizumab may be at risk of serious, and in some cases fatal, pulmonary haemorrhage/haemoptysis.
Croatian: Bolesnici s rakom pluća nemalih stanica koji se liječe bevacizumabom mogu biti izloženi riziku od ozbiljnog, a u nekim slučajevima i smrtonosnog plućnog krvarenja/hemoptize.
English: ● if you have or have had pain in the mouth, teeth and/or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth tell your doctor and dentist immediately.
Croatian: ● ako osjećate ili ste osjećali bol u ustima, zubima i/ili čeljusti, ako imate otekline ili ranice u usnoj šupljini, ako osjećate utrnulost ili težinu u čeljusti, ili Vam se klima zub, odmah obavijestite svog liječnika i stomatologa,
English: Grade 3 proteinuria was reported in up to 10.9% of treated patients.
Croatian: Proteinurija stupnja 3 prijavljena je u najviše 10,9 % liječenih bolesnika.
English: During the trial, of the patients who received trial treatment, 32.2% (136/422) of patients received 7-12 administrations of bevacizumab and 21.1% (89/422) of patients received 13 or more administrations of bevacizumab.
Croatian: Od bolesnika koji su tijekom ispitivanja primali ispitivani lijek, njih 32,2 % (136/422) je primilo između 7 i 12 aplikacija bevacizumaba, a 21,1 % (89/422) 13 ili više aplikacija bevacizumaba.
English: Zirabev infusions should not be administered or mixed with glucose solutions.
Croatian: Infuzije lijeka Zirabev ne smiju se primjenjivati niti miješati s otopinama glukoze.
English: The necessary amount of bevacizumab should be withdrawn and diluted to the required administration volume with sodium chloride 9 mg/ml (0.9%) solution for injection.
Croatian: Treba izvući potrebnu količinu bevacizumaba i razrijediti je otopinom natrijevog klorida za injekciju od 9 mg/ml (0,9 %) do volumena potrebnog za primjenu.
English: No clinically relevant interaction of bevacizumab was observed on the pharmacokinetics of co-administered interferon alpha 2a, erlotinib (and its active metabolite OSI-420), or the chemotherapies irinotecan (and its active metabolite SN38), capecitabine, oxaliplatin (as determined by measurement of free and total platinum), and cisplatin.
Croatian: Nije opažena klinički značajna interakcija bevacizumaba na farmakokinetiku istodobno primijenjenog interferona alfa-2a, erlotiniba (i njegovog aktivnog metabolita OSI-420) ni kemoterapeutika irinotekana (i njegovog aktivnog metabolita SN38), kapecitabina, oksaliplatina (što je utvrđeno određivanjem slobodne platine i ukupne platine) i cisplatina.
English: Patients receiving bevacizumab plus chemotherapy, with a history of arterial thromboembolism, diabetes or age greater than 65 years have an increased risk of developing arterial thromboembolic reactions during therapy.
Croatian: Bolesnici koji primaju bevacizumab zajedno s kemoterapijom i koji u anamnezi imaju arterijsku tromboemboliju, dijabetes ili su stariji od 65 godina imaju povećan rizik za razvoj arterijskih tromboembolijskih reakcija tijekom liječenja.
English: The initial dose should be delivered over 90 minutes as an intravenous infusion.
Croatian: Početna doza se mora primijeniti intravenskom infuzijom tijekom 90 minuta.
English: If a dose of Zirabev is missed
Croatian: Ako ste propustili dozu lijeka Zirabev
English: Zirabev must be administered under the supervision of a physician experienced in the use of antineoplastic medicinal products.
Croatian: Zirabev mora se primjenjivati pod nadzorom liječnika s iskustvom u primjeni antitumorskih lijekova.
English: Zirabev will be administered together with a chemotherapy regimen containing platinum.
Croatian: Zirabev će se davati zajedno s režimom kemoterapije koji sadrži platinu.
English: Individual cases and clusters of serious ocular adverse reactions have been reported following unapproved intravitreal use of bevacizumab compounded from vials approved for intravenous administration in cancer patients.
Croatian: Prijavljeni su pojedinačni slučajevi i skupine ozbiljnih očnih nuspojava nakon neodobrene intravitrealne primjene bevacizumaba pripremljenog iz bočica odobrenih za intravensku primjenu u bolesnika s malignom bolešću.
English: ● an abnormal tube-like connection or passage between the windpipe and the gullet, between internal organs and skin, between the vagina and any parts of the gut or between other tissues that are not normally connected (fistula), and are judged by your doctor to be severe,
Croatian: ● u slučaju pojave neuobičajenog spoja ili kanala u obliku cjevčice između dušnika i jednjaka, između unutarnjih organa i kože, između rodnice i bilo kojeg dijela probavnog sustava ili između drugih tkiva koja inače nisu povezana (fistula), a koje Vaš liječnik smatra teškim,
English: All of these findings were reversible upon discontinuation of bevacizumab and sunitinib malate (see Hypertension, Proteinuria, PRES in section 4.4).
Croatian: Svi su ovi nalazi bili reverzibilni po prestanku primjene bevacizumaba i sunitinibmalata (vidjeti Hipertenzija, Proteinurija i Sindrom posteriorne reverzibilne encefalopatije u dijelu 4.4).
English: However, somnolence and syncope have been reported with bevacizumab use (see table 1 in section 4.8).
Croatian: Međutim, tijekom primjene bevacizumaba prijavljene su somnolencija i sinkopa (vidjeti tablicu 1 u dijelu 4.8).
English: Prior anthracyclines exposure and/or prior radiation to the chest wall may be possible risk factors for the development of CHF.
Croatian: Prethodna izloženost antraciklinima i/ili prethodno zračenje stijenke prsnog koša mogući su čimbenici rizika za razvoj kongestivnog zatajenja srca.
English: No significant difference was observed in the duration of overall survival between patients who received bevacizumab monotherapy compared to patients treated with FOLFOX-4.
Croatian: Nije opažena značajna razlika u duljini ukupnog preživljenja između bolesnika koji su primali bevacizumab u monoterapiji i bolesnika liječenih režimom FOLFOX-4.
English: In study JO25567, all grade hypertension was observed in 77.3% of the patients who received bevacizumab in combination with erlotinib as first-line treatment for non-squamous NSCLC with EGFR activating mutations, compared to 14.3% of patients treated with erlotinib alone.
Croatian: U ispitivanju JO25567, hipertenzija svih stupnjeva primijećena je u 77,3 % bolesnika koji su primali bevacizumab u kombinaciji s erlotinibom kao prvu liniju liječenja neskvamoznog NSCLCa s aktivirajućim mutacijama EGFR-a u usporedbi s 14,3 % bolesnika liječenih samo erlotinibom.
English: If the 60-minute infusion is well tolerated, all subsequent infusions may be administered over 30 minutes.
Croatian: Ako je bolesnik dobro podnio 60-minutnu infuziju, sve sljedeće infuzije mogu se primijeniti tijekom 30 minuta.
English: ● It is possible that Zirabev can increase the risk of bleeding in your lungs, including coughing or spitting blood.
Croatian: Zirabev može povećati rizik od krvarenja u plućima, uključujući iskašljavanje krvi ili krvavi ispljuvak.
English: At the time of the final primary analysis, the primary endpoint of EFS by independent central review did not show a statistically significant difference between the two treatment arms, with HR of 0.93 (95% CI: 0.61, 1.41; p-value = 0.72).
Croatian: U trenutku završne primarne analize, za primarnu mjeru ishoda, preživljenje bez događaja prema ocjeni neovisnog središnjeg povjerenstva, nije bilo statistički značajne razlike između dvije liječene skupine, uz HR 0,93 (95% CI: 0,61; 1.41; p-vrijednost = 0,72).
English: Each pack of Zirabev contains one vial.
Croatian: Svako pakiranje lijeka Zirabev sadrži jednu bočicu.
English: UNITED STATES
Croatian: Sjedinjene Američke Države
English: Warnings and precautions Talk to your doctor, pharmacist or nurse before using Zirabev:
Croatian: Upozorenja i mjere opreza Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego primite Zirabev.
English: b For additional information refer below within section “Further information on selected serious adverse reactions”
Croatian: Za dodatne informacije vidjeti dio „Dodatne informacije o odabranim ozbiljnim nuspojavama“ u nastavku.
English: Bevacizumab has not been shown to reduce your ability to drive or to use any tools or machines.
Croatian: Nije se pokazalo da bevacizumab smanjuje sposobnost upravljanja vozilima i rukovanja alatima ili strojevima.
English: While the incidence of CHF was, in both arms, above that previously observed for doxorubicin therapy, the rate was higher in the R-CHOP plus bevacizumab arm.
Croatian: Dok je incidencija kongestivnog zatajenja srca u obje skupine bila viša od one prethodno liječenja kod terapije doksorubicinom, stopa je bila veća u skupini koja je primala R-CHOP uz bevacizumab.
English: The primary endpoint of this trial was progression free survival (PFS), based on trial investigators' assessment of disease progression.
Croatian: Primarna mjera ishoda ovog ispitivanja bilo je preživljenje bez progresije bolesti, na temelju procjene progresije bolesti od strane ispitivača.
English: Hazard ratio (97.5% CI)
Croatian: Omjer hazarda (97,5 % CI)
English: Decreased neutrophil count, decreased white blood cell count and presence of urine protein may be associated with bevacizumab treatment.
Croatian: Smanjen broj neutrofila, smanjen broj leukocita i prisutnost proteina u mokraći mogu biti povezani s liječenjem bevacizumabom.
English: In terms of safety, there was a higher overall incidence of Grade 3-5 AEs in study E3200 relative to study ML18147.
Croatian: Što se tiče sigurnosti primjene, u ispitivanju E3200 ukupna incidencija štetnih događaja stupnja 3-5 bila je veća nego u ispitivanju ML18147.
English: In the bevacizumab-containing arms, patients could receive bevacizumab as a single-agent every 3 weeks until disease progression or unacceptable toxicity.
Croatian: U skupinama koje su primale bevacizumab bolesnici su mogli dobivati bevacizumab kao jedini lijek svaka 3 tjedna do progresije bolesti ili razvoja neprihvatljive toksičnosti.
English: Trial results show that 94% (277 / 296) of eligible patients went on to receive single agent bevacizumab at cycle 7.
Croatian: Rezultati ispitivanja pokazuju da je 94 % (277/296) bolesnika koji su ispunjavali uvjete u 7. ciklusu nastavilo liječenje samo bevacizumabom.
English: In bevacizumab clinical trials, gastrointestinal fistulae (all grade) have been reported with an incidence of up to 2% in patients with metastatic colorectal cancer and ovarian cancer, but were also reported less commonly in patients with other types of cancer.
Croatian: U kliničkim ispitivanjima bevacizumaba prijavljen je nastanak gastrointestinalnih fistula (svih stupnjeva) s incidencijom do 2 % u bolesnika s metastatskim kolorektalnim rakom i rakom jajnika, no one su prijavljene manje često i u bolesnika s drugim oblicima raka.
English: Table 4 Efficacy results for trial AVF2107g
Croatian: Tablica 4. Rezultati djelotvornosti za ispitivanje AVF2107g
English: Patients with central nervous system metastases, including previously treated or resected brain lesions, were excluded.
Croatian: U ispitivanje nisu bile uključene bolesnice s metastazama u središnjem živčanom sustavu, uključujući prethodno liječene ili odstranjene lezije mozga.
English: Arm 2 IFL + bevacizumaba
Croatian: Skupina 2 IFL + bevacizumab
English: Adjustment for these baseline factors resulted in a treatment hazard ratio of 0.78 (95% CI [0.63; 0.96], p=0.0219), indicating a 22% reduction in the risk of death for patients in the bevacizumab + IFN alfa-2a arm compared to IFN alfa-2a arm.
Croatian: Nakon prilagodbe za navedene ishodišne čimbenike dobiven je omjer hazarda liječenja od 0,78 (95% CI [0,63;0,96]; p = 0,0219), koji ukazuje da je rizik od smrti u skupini bevacizumab + IFN alfa-2a bio 22% manji nego u skupini bolesnika koji su primali IFN alfa-2a.